<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783392</url>
  </required_header>
  <id_info>
    <org_study_id>STH16245</org_study_id>
    <nct_id>NCT01783392</nct_id>
  </id_info>
  <brief_title>Peripheral Electrical Stimulation for the Treatment of Overactive Bladder</brief_title>
  <acronym>PESTOB</acronym>
  <official_title>Peripheral Electrical Stimulation for the Treatment of Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <brief_summary>
    <textblock>
      This clinical trial testing three different sites of transcutaneous electrical nerve
      stimulation for the treatment of overactive bladder (OAB).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of voiding</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <description>The change of urinary frequency from baseline to after 4 weeks of the treatment, measured by a 3 days bladder diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient Perception of Bladder Condition (PPBC)</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <description>Change in the patient's bladder condition based on the PPBC questionaire from baseline to after 4 weeks of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in symptom severity score and health-related quality of life score (HRQL) based on OAB-questionnaire</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <description>Change in symptom severity score and HRQL score from baseline to after 4weeks of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the mental/physical scores of RAND36</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary symptoms score and bother symptom score based on the ICIQ-OAB questionnaire</measure>
    <time_frame>baseline, 4 weeks</time_frame>
    <description>Change in urinary symptoms score and bother symptom score based on the ICIQ-OAB questionnaire from baseline to after 4 weeks of the treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Idiopathic Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Unilateral Posterior Tibial Nerve Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilateral Posterior Tibial Nerve Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shoulder stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcutaneous Electrical Nerve Stimulation</intervention_name>
    <arm_group_label>Unilateral Posterior Tibial Nerve Stimulation</arm_group_label>
    <arm_group_label>Bilateral Posterior Tibial Nerve Stimulation</arm_group_label>
    <arm_group_label>Shoulder stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females, at least 18 years of age

          -  Documented symptoms of idiopathic overactive bladder for at least 3 months

          -  Failure on primary OAB treatment, such as behavior modification or fluid/diet
             management

          -  Patients can remain on stable medication

          -  Willing and capable of understanding and complying with all requirements of the
             protocol

          -  Signed Informed Consent to participate in the study after full discussion of the
             research nature of the treatment and its risks and benefits

        Exclusion Criteria:

          -  Urinary retention or post voiding residual greater than 100 ml

          -  Clinically significant bladder outlet obstruction

          -  Stress predominant mixed urinary incontinence

          -  Neurological disease affecting urinary bladder function, including but not limited to
             Parkinson's disease, multiple sclerosis, stroke, spinal cord injury.

          -  Pelvic surgery (such as sub-urethral sling, pelvic floor repair) within the past 6
             months

          -  Denovo OAB following pelvic surgery sub-urethral sling Intravesical or urethral
             sphincter Botulinum Toxin Type A injections within the past 6 months

          -  Percutaneous Tibial Nerve Stimulation (PTNS) therapy for overactive bladder within the
             past 6 months

          -  Any form of electric stimulation to the pelvis or lower limbs within 4 weeks

          -  Vaginal prolapse greater than Stage II in the anterior compartment of the vagina using
             International Continence Society (ICS) Pelvic Organ ProlapseQuantification (POPQ)
             criteria.

          -  Prior periurethral or transurethral bulking agent injections for bladder problems
             within the past 12 months.

          -  History of pelvic radiation therapy

          -  Any skin conditions affecting treatment sites

          -  Lacking dexterity to properly utilize the components of the stimulator system.

          -  Presence of an implanted electro-medical device (e.g. pacemaker, defibrillator,
             InterStimÂ®, etc.),

          -  Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to
             become pregnant during the course of the study.

          -  Recurrent Urinary Tract Infections UTI (&gt;3 UTI's in the past year)

          -  History of, or current, lower tract genitourinary malignancies

          -  Any clinically significant systemic disease or condition that in the opinion of the
             Investigator would make the patient unsuitable for the study

          -  Any other clinical trial within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Chapple</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Teaching Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS foundation Trust, Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>transcutaneous posterior tibial nerve stimulation</keyword>
  <keyword>placebo PTNS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

